Pfizer Offers Government A "Not-For-Profit" Price For Roll-Out Of Its Two-Dose mRNA COVID-19 Vaccine In India

United States (US) based pharmaceutical giant Pfizer said on Thursday (22 April) that it has offered a not-for-profit price for its COVID-19 vaccine to the Indian government and that it is in talks with the administration to deploy its vaccine for the ongoing nationwide inoculation drive, reports Hindustan Times.

Pfizer in a collaboration with BioNTech has developed a two-dose mRNA vaccine that has been widely used in the US, Europe, Israel and other countries. The Pfizer Covid-19 vaccine has an efficacy of 95 per cent against the disease.

Its statement read, "During the current pandemic situation worldwide, Pfizer has maintained that its priority would be to exclusively support governments through the supply of its vaccine only to governments for their immunisation programs. This would be our approach in India as well."

Pfizer's move comes after the government on 13 April announced that Covid-19 vaccines cleared for use in the US, the UK, the European Union, and Japan will get fast-track approval in India, and would not need prior bridging trial results to seek emergency use authorization (EUA).